Beyond Thinking
Welcome to Beyond Blue’s Thought Leadership Hub, where we highlight complex concepts with clarity and showcase our commitment to delivering excellence with ease. Explore our insights, discover innovative perspectives and join us on a journey to navigate the intricate with confidence.
When the Gates Stay Closed: Strategic guidance on what to do when launch delays hit
Author: Alex Hunt, Research Manager, Beyond Blue Strategy In the recent article from our Beyond Neurology team, we traced the journey of BTK inhibitors (BTKi) in Multiple Sclerosis (MS), a story marked by scientific promise, high expectations, and a few sharp turns...
CoLoop vs Professional Translation: A pragmatic comparison for researchers
Author: Mike Pepp, Senior Commercial Consultant, Beyond Blue Like many agencies, we are always striving to use new technologies that reduce time to insight – balancing this with the need to have confidence that the quality of our learnings and insights is maintained...
ESMO 2025: Ones to watch
Explore the headlines set to surface at ESMO 2025. ADCs make their move into early-stage disease Drugs like Enhertu and Padcev, already headline-makers in metastatic disease, are now making waves in early-stage settings. DESTINY-Breast05, DESTINY-Breast11, and...
Spotlight on BTK Inhibitors in MS
In recent years, interest in BTK inhibitors (BTKi) for MS has surged, with hopes that they could offer a new way to tackle the underlying drivers of the disease. But the journey, so far, has been a rollercoaster, and the delayed FDA decision on tolebrutinib marks the...
Smarter Tools, Smarter Care: How Innovation is Transforming Prostate Cancer
From early detection to advanced therapy, prostate cancer care is being reshaped by smarter tools that provide deeper insight and more precise interventions. These advances are enabling clinicians to act sooner, tailor treatment more accurately, and expand options for...
The Power of Words: In sickness and in health
Author: Sam Hope, CEO, Beyond Blue Why is it that some people will happily stick to collagen powders and herbal elixirs but skip life-saving medication? This puzzling question became the spark for our self-funded study. Watching my own mother consistently and...
Data Dump to Strategic Clarity: Make patient chart audits work for you
When you're sitting on hundreds, sometimes thousands, of patient records, the challenge isn’t just collecting the data, or even analysing it. It’s making it usable. Beyond Blue helps you turn complex chart audit data into clear, actionable insight. No more 300-slide...
More Bang for Your Behavioural Buck: Connecting COM-B to the Behaviour Change Wheel and Behaviour Change Taxonomy
COM-B has rightly become a cornerstone of behaviour change in market research projects. It allows a seamless transition from insight to practical implementation by pinpointing where to focus behaviour change efforts. While COM-B is widely used, integrating it with the...
ASCO 2025: Key market shifts and strategic considerations
ADCs step into first-line mBC ASCO 2025 highlighted the growing role of ADCs in reshaping metastatic breast cancer treatment. Two key trials, DESTINY-Breast09 and ASCENT-04, showed strong efficacy for ADCs in 1L HER2+ mBC and PD-L1+ TNBC respectively, raising the...
